Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PG-NS (Porphyrin-derived Graphene-like Nanosheets) is an experimental nanostructured organic therapeutic platform designed for the treatment of radiation-induced mucositis. The platform consists of graphene-like nanosheets synthesized using porphyrin templates, which are functionalized with CD63-specific aptamers. This design enables PG-NS to selectively capture and sequester small extracellular vesicles (sEVs) released from radiation-damaged tissues, thereby preventing the activation of the STING (stimulator of interferon genes) pathway in macrophages and suppressing excessive inflammation. Additionally, the porphyrin-derived structure of the nanosheets allows them to act as scavengers for reactive oxygen species (ROS) and reactive nitrogen species (RNS), providing a dual-action approach to mitigating mucosal damage and improving quality of life for patients undergoing radiotherapy for head and neck cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PG-NS.